Quent Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Quent Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,110	Closed	-$45.9K	–	1339
2023 Q3	$45.9K	Hold	4,110	–	–	0.01%	604
2023 Q2	$88K	Hold	4,110	–	–	0.01%	451
2023 Q1	$161K	Hold	4,110	–	–	0.03%	319
2022 Q4	$191K	Hold	4,110	–	–	0.04%	280
2022 Q3	$213K	Hold	4,110	–	–	0.04%	234
2022 Q2	$194K	Hold	4,110	–	–	0.04%	238
2022 Q1	$293K	Hold	4,110	–	–	0.05%	211
2021 Q4	$307K	Buy	+4,110	New	+$323K	0.06%	215

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quent Capital's ENTA Position: Q4 2023 in Review

Quent Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 4,110 shares — an estimated $45.9K sold.

Quent Capital first reported a position in ENTA in Q4 2021 and held it in 8 quarters. The position peaked at $307K in Q4 2021. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

Quent Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Quent Capital sold 4,110 Enanta Pharmaceuticals shares in Q4 2023, an estimated $45.9K.
Quent Capital first reported a position in Enanta Pharmaceuticals in Q4 2021 and held it in 8 quarters.
Quent Capital's Enanta Pharmaceuticals position peaked at $307K in Q4 2021.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Quent Capital's 13F filing for Q4 2023, filed 19 Jan 2024.